JP2024504331A5 - - Google Patents
Info
- Publication number
- JP2024504331A5 JP2024504331A5 JP2023544026A JP2023544026A JP2024504331A5 JP 2024504331 A5 JP2024504331 A5 JP 2024504331A5 JP 2023544026 A JP2023544026 A JP 2023544026A JP 2023544026 A JP2023544026 A JP 2023544026A JP 2024504331 A5 JP2024504331 A5 JP 2024504331A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- use according
- seq
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021073083 | 2021-01-21 | ||
| CNPCT/CN2021/073083 | 2021-01-21 | ||
| CN2021073308 | 2021-01-22 | ||
| CNPCT/CN2021/073308 | 2021-01-22 | ||
| CN2021074141 | 2021-01-28 | ||
| CNPCT/CN2021/074141 | 2021-01-28 | ||
| CN2021074644 | 2021-02-01 | ||
| CNPCT/CN2021/074644 | 2021-02-01 | ||
| CN2021075310 | 2021-02-04 | ||
| CNPCT/CN2021/075310 | 2021-02-04 | ||
| CN2021091822 | 2021-05-05 | ||
| CNPCT/CN2021/091822 | 2021-05-05 | ||
| CNPCT/CN2021/109322 | 2021-07-29 | ||
| CN2021109322 | 2021-07-29 | ||
| PCT/CN2022/072869 WO2022156726A1 (en) | 2021-01-21 | 2022-01-20 | Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504331A JP2024504331A (ja) | 2024-01-31 |
| JP2024504331A5 true JP2024504331A5 (enExample) | 2025-03-07 |
Family
ID=82548518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544026A Withdrawn JP2024504331A (ja) | 2021-01-21 | 2022-01-20 | 抗ｐｄ１抗体と組み合わせて抗ｔｉｇｉｔ抗体を使用するがん処置方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230391883A1 (enExample) |
| EP (1) | EP4281189A4 (enExample) |
| JP (1) | JP2024504331A (enExample) |
| KR (1) | KR20230158464A (enExample) |
| CN (1) | CN117177770A (enExample) |
| AU (1) | AU2022211109A1 (enExample) |
| BR (1) | BR112023014582A2 (enExample) |
| CO (1) | CO2023009626A2 (enExample) |
| IL (1) | IL304600A (enExample) |
| MX (1) | MX2023008597A (enExample) |
| PE (1) | PE20240659A1 (enExample) |
| TW (1) | TW202243691A (enExample) |
| WO (1) | WO2022156726A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115746144B (zh) * | 2022-09-02 | 2026-01-02 | 安徽瀚海博兴生物技术有限公司 | 抗tigit-pd1双特异性抗体及其应用 |
| CN121219319A (zh) * | 2023-06-27 | 2025-12-26 | 正大天晴药业集团股份有限公司 | 抗tigit抗体及其应用 |
| CN121003695A (zh) * | 2024-05-24 | 2025-11-25 | 百奥泰生物制药股份有限公司 | 抗tigit抗体和抗pd-1抗体联合治疗肿瘤 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI888366B (zh) * | 2013-07-16 | 2025-07-01 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法 |
| TWI816729B (zh) * | 2017-12-30 | 2023-10-01 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
| EP3746119A4 (en) * | 2018-02-01 | 2021-11-10 | Merck Sharp & Dohme Corp. | METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY |
| KR102184377B1 (ko) * | 2018-02-19 | 2020-11-30 | 고려대학교 산학협력단 | 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도 |
| MX2020008882A (es) * | 2018-02-26 | 2021-01-08 | Genentech Inc | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. |
| CN108840932B (zh) * | 2018-04-28 | 2022-03-29 | 中国科学院微生物研究所 | 一种pd-1特异性抗体及其抗肿瘤应用 |
| CN111196852A (zh) * | 2018-11-16 | 2020-05-26 | 四川科伦博泰生物医药股份有限公司 | 抗tigit抗体及其用途 |
| CN111744013B (zh) * | 2019-03-29 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合 |
| CN112618577B (zh) * | 2020-12-15 | 2023-07-25 | 深圳君拓生物科技有限公司 | 动物双歧杆菌在提高肿瘤免疫治疗应答中的作用 |
-
2022
- 2022-01-20 PE PE2023002129A patent/PE20240659A1/es unknown
- 2022-01-20 US US18/262,236 patent/US20230391883A1/en active Pending
- 2022-01-20 WO PCT/CN2022/072869 patent/WO2022156726A1/en not_active Ceased
- 2022-01-20 KR KR1020237025107A patent/KR20230158464A/ko active Pending
- 2022-01-20 JP JP2023544026A patent/JP2024504331A/ja not_active Withdrawn
- 2022-01-20 EP EP22742205.2A patent/EP4281189A4/en not_active Withdrawn
- 2022-01-20 BR BR112023014582A patent/BR112023014582A2/pt unknown
- 2022-01-20 MX MX2023008597A patent/MX2023008597A/es unknown
- 2022-01-20 CN CN202280010805.7A patent/CN117177770A/zh active Pending
- 2022-01-20 AU AU2022211109A patent/AU2022211109A1/en not_active Abandoned
- 2022-01-20 TW TW111102344A patent/TW202243691A/zh unknown
-
2023
- 2023-07-19 CO CONC2023/0009626A patent/CO2023009626A2/es unknown
- 2023-07-19 IL IL304600A patent/IL304600A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024037894A5 (enExample) | ||
| JP2023113893A5 (enExample) | ||
| IL276830B1 (en) | Anti-claudin 18.2 antibodies and their uses | |
| JP2020019787A5 (enExample) | ||
| JP2021521843A5 (enExample) | ||
| JP2020528750A5 (enExample) | ||
| JP2020514310A5 (enExample) | ||
| JP2021524256A5 (enExample) | ||
| JP2022116269A5 (enExample) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| CN109843927A (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| JP2017535257A5 (enExample) | ||
| JP2023503396A5 (enExample) | ||
| JP2022516351A5 (enExample) | ||
| JP2025038088A5 (enExample) | ||
| JP2023543826A5 (enExample) | ||
| JP2024540148A5 (enExample) | ||
| JP2024533067A5 (enExample) | ||
| JP2021512652A5 (enExample) | ||
| JP2022519631A5 (enExample) | ||
| JP2025511288A5 (enExample) | ||
| JP2023502323A5 (enExample) | ||
| JP2025504496A5 (enExample) | ||
| JP2025520232A5 (enExample) |